Radionuclide imaging Book Section

  


Authors: Carrasquillo, J. A.; Weiner, R. E.; McAreavey, D.; Neumann, R. D.
Editor: Magrath, I. T.
Article/Chapter Title: Radionuclide imaging
Abstract: The nuclear medicine tests available for staging and posttreatment evaluation of lymphoma patients are generally most useful when they are used to survey the patient for unsuspected sites of disease and/or to evaluate a physiologic or biochemical parameter to determine whether a suspected site or lesion found by an anatomic structural imaging test, such as computed tomography (CT) or magnetic resonance imaging (MRI), represents viable tumor tissue. Nuclear medicine tests are notable for relatively high sensitivity in detecting active disease but these tests often have low specificities. The multiplicity of possible disease locations in lymphomas and the wide variety of clinical presentations preclude a simple scheme for using nuclear medicine tests in the evaluation of each and every patient. We will thus discuss briefly some of the nuclear medicine tests available, their likely application, and give an indication of effectiveness. We shall begin with the most widely used of these, 2-[18F] fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET), which has widespread application in lymphoma patient evaluation and is now generally available. © 2010 by Taylor & Francis Group, LLC.
Book Title: The Lymphoid Neoplasms. 3rd ed
ISBN: 9780340809471
Publisher: CRC Press/Taylor & Francis Group  
Publication Place: Boca Raton, FL
Date Published: 2010-01-01
Start Page: 790
End Page: 808
Language: English
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056031783&doi=10.1201%2fb13424&partnerID=40&md5=e2f3b2a9e02f050f3e5629114aaeed75
Notes: Book Chapter: 45 -- Export Date: 3 December 2018 -- Source: Scopus